Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00756665 · ClinicalTrials.gov registry record
Prostate Active Surveillance Study
A clinical trial of Prostatic Neoplasms, sponsored by University of Washington.
- Recruiting
- Registry status
- 3,000
- Enrollment target
- 11
- Study locations
NCT00756665 is a study of Prostatic Neoplasms that is actively recruiting participants, run by University of Washington. The registered enrollment target is 3,000 participants, above the 468-participant average among 65 other Prostatic Neoplasms trials with a reported enrollment target (541% higher). The trial reports 11 study locations across 8 states.
The verdict
NCT00756665, a study of Prostatic Neoplasms, is actively recruiting participants, sponsored by University of Washington.
- RECRUITING
- Registry status
- 3,000 participants
- Enrollment target
- 11
- Study locations
Study Summary
The Prostate Active Surveillance Study (PASS) is a research study for men who have chosen active surveillance as a management plan for their prostate cancer. Active surveillance is defined as close monitoring of prostate cancer with the offer of treatment if there are changes in test results. This study seeks to discover markers that will identify cancers that are more aggressive from those tumors that grow slowly.
Conditions Studied
Study Locations (11)
California
- Veterans Affairs San Francisco Health Care System - San Francisco
- University of California, San Francisco - San Francisco
- Stanford University - Stanford
Washington
- Veterans Affairs Puget Sound Health Care System - Seattle
- University of Washington - Seattle
Georgia
- Emory University - Atlanta
Massachusetts
- Beth Israel Deaconess Medical Center/Harvard Medical School - Boston
Michigan
- University of Michigan - Ann Arbor
Texas
- University of Texas Health Science Center, San Antonio - San Antonio
Virginia
- Eastern Virginia Medical School - Norfolk
British Columbia
- University of British Columbia - Vancouver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,000 participants |
| Start Date | 2008-07 |
| Est. Completion | 2032-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00756665
The ClinicalTrials.gov registry entry for NCT00756665 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 3,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 468-participant average among 65 other Prostatic Neoplasms trials with a reported enrollment target (541% higher). The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostatic Neoplasms appearing as the primary indexed condition, and to 0 interventions.
NCT00756665 reports 11 study locations spanning 8 distinct geographic areas - top geographies include California, Washington, Georgia.
Frequently Asked Questions
What is clinical trial NCT00756665 about?
NCT00756665 is a clinical study titled "Prostate Active Surveillance Study". The Prostate Active Surveillance Study (PASS) is a research study for men who have chosen active surveillance as a management plan for their prostate cancer. Active surveillance is defined as close monitoring of prostate cancer with the offer of treatment if there are changes in test results. This s...
What is the current status of trial NCT00756665?
This trial is currently recruiting. The enrollment target is 3,000 participants. The study started on 2008-07. Estimated completion is 2032-09.
What conditions does trial NCT00756665 study?
This clinical trial studies the following conditions: Prostatic Neoplasms.
Who is sponsoring clinical trial NCT00756665?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00756665 being conducted?
This trial has 11 study locations across California, Georgia, Massachusetts, Michigan, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostatic Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617
RECRUITING · Phase 1
-
Men With Prostate Cancer: Optimizing Wellness by Enhanced Relief From Hot Flashes With Acupuncture
RECRUITING · NA
-
A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer
RECRUITING · Phase 1
-
A Study to Learn About Real-world Utilization and Outcomes of Darolutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) for Newly Diagnosed Metastatic Hormone-sensitive Prostate Cancer (de Novo mHSPC) in US Urology Clinics
RECRUITING
-
Men at High Genetic Risk for Prostate Cancer
RECRUITING
-
A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.